
The Science of Psychedelics for Mental Health | Dr. Robin Carhart-Harris
Andrew Huberman (host), Robin Carhart-Harris (guest), Narrator, Narrator
In this episode of Huberman Lab, featuring Andrew Huberman and Robin Carhart-Harris, The Science of Psychedelics for Mental Health | Dr. Robin Carhart-Harris explores psychedelics Rewire Depressed Brains: Inside Carhart-Harris’ Groundbreaking Trials Andrew Huberman interviews Dr. Robin Carhart-Harris about the science, mechanisms, and clinical applications of classic psychedelics such as psilocybin, LSD, and DMT, with a focus on depression and other difficult-to-treat conditions. Carhart-Harris explains what “psychedelic” really means, why subjective experience and ego dissolution matter, and how serotonin 2A receptor activation alters brain network dynamics. They review controlled trials showing rapid, often dramatic improvements in major depression, treatment-resistant depression, PTSD, anorexia, and fibromyalgia, and contrast macrodosing with the more weakly supported practice of microdosing. The conversation concludes with emerging data on structural brain changes after a single psilocybin session, the coming FDA decisions on MDMA and psilocybin therapies, and the ethical, regulatory, and practical challenges of integrating these treatments into mainstream psychiatry.
Psychedelics Rewire Depressed Brains: Inside Carhart-Harris’ Groundbreaking Trials
Andrew Huberman interviews Dr. Robin Carhart-Harris about the science, mechanisms, and clinical applications of classic psychedelics such as psilocybin, LSD, and DMT, with a focus on depression and other difficult-to-treat conditions. Carhart-Harris explains what “psychedelic” really means, why subjective experience and ego dissolution matter, and how serotonin 2A receptor activation alters brain network dynamics. They review controlled trials showing rapid, often dramatic improvements in major depression, treatment-resistant depression, PTSD, anorexia, and fibromyalgia, and contrast macrodosing with the more weakly supported practice of microdosing. The conversation concludes with emerging data on structural brain changes after a single psilocybin session, the coming FDA decisions on MDMA and psilocybin therapies, and the ethical, regulatory, and practical challenges of integrating these treatments into mainstream psychiatry.
Key Takeaways
Classic Psychedelics Are Defined Both by Receptor Pharmacology and Subjective Experience
Carhart-Harris emphasizes that “classic psychedelics” are best defined in two ways: pharmacologically, as agonists at the serotonin 2A receptor (e. ...
Get the full analysis with uListen AI
Psilocybin Macrodosing Shows Strong, Replicable Antidepressant Effects
In treatment-resistant and major depression, two guided psilocybin sessions (typically 25 mg, spaced 1–3 weeks apart) produce high remission rates—often around 60–70% in small trials—far exceeding typical SSRI outcomes in similar populations. ...
Get the full analysis with uListen AI
Microdosing Benefits Are Weak and Largely Explained by Expectation
A creative citizen-science study led by Carhart-Harris’ group asked LSD microdosers to self-blind by encapsulating their own microdoses and placebos and tracking outcomes. ...
Get the full analysis with uListen AI
Psychedelics Temporarily Increase Brain Entropy and Global Connectivity, Then Leave Lasting Network Changes
Neuroimaging during psilocybin, LSD, and DMT shows decreased modularity and increased “global functional connectivity”: brain regions that normally communicate mostly within their own networks start communicating across networks. ...
Get the full analysis with uListen AI
A Single High-Dose Psilocybin Session Can Induce Structural Brain Changes
In a completed but not yet published study of healthy, psychedelic-naïve middle-aged volunteers, one 25 mg psilocybin session produced measurable changes in white matter tracts between prefrontal cortex, thalamus, and striatum, assessed via diffusion tensor imaging. ...
Get the full analysis with uListen AI
Therapeutic Setting, Music, and ‘Trust, Let Go, Be Open’ Are Not Optional Extras
Across modern psilocybin trials, the core protocol is highly consistent: two trained guides, a safe clinical room, an eye mask, curated non-lyrical music, preparation sessions, and post-session integration. ...
Get the full analysis with uListen AI
Regulatory Change Is Imminent for MDMA, Coming Later for Psilocybin
MAPS has completed two phase 3 trials of MDMA-assisted therapy for PTSD, with remission rates around two-thirds and durable benefits. ...
Get the full analysis with uListen AI
Notable Quotes
“Psychedelic literally means ‘mind-revealing’—these drugs make aspects of the psyche visible that are ordinarily not available to us.”
— Dr. Robin Carhart-Harris
“If it wasn’t for this action of the classic psychedelics—this revealing of the unconscious—I don’t think we’d be so interested in them.”
— Dr. Robin Carhart-Harris
“Science is not about what you want to believe. That right there is the beauty of science.”
— Dr. Robin Carhart-Harris
“Psychedelic therapy allows you to sit with rather than sit on [your pain], in a way that chronic pharmacotherapy often does not.”
— Dr. Robin Carhart-Harris
“Current treatments haven’t really progressed since the 1950s. Psychedelic therapy is a genuine paradigm challenge to that model of a pill every day.”
— Dr. Robin Carhart-Harris
Questions Answered in This Episode
In your depression trials, what specific qualitative features of a psilocybin session (e.g., confronting trauma vs. mystical-type experiences) best predict who will still be in remission six months or a year later?
Andrew Huberman interviews Dr. ...
Get the full analysis with uListen AI
Given your findings that pre-session expectancy predicts SSRI outcomes but not psilocybin outcomes, how should clinicians practically manage and frame expectations for patients considering psychedelic therapy?
Get the full analysis with uListen AI
Your DTI results suggest structural changes in prefrontal–thalamic/striatal tracts after a single psilocybin session; what is your working hypothesis about how these anatomical shifts translate into specific changes in cognition or emotional regulation?
Get the full analysis with uListen AI
How do you think psychedelic therapy should be integrated into existing treatment algorithms—for example, should psilocybin be reserved for treatment-resistant cases, or do your data argue for moving it earlier in the sequence for certain diagnoses like anorexia or PTSD?
Get the full analysis with uListen AI
With startups racing to develop ‘non-hallucinogenic psychedelics,’ what empirical tests or trial designs would you consider decisive in determining whether subjective psychedelic experience is truly dispensable for long-term therapeutic benefit?
Get the full analysis with uListen AI
Transcript Preview
(music plays) Welcome to the Huberman Lab Podcast, where we discuss science and science-based tools for everyday life. I'm Andrew Huberman, and I'm a professor of neurobiology and ophthalmology at Stanford School of Medicine. Today, my guest is Dr. Robin Carhart-Harris. Dr. Carhart-Harris is a distinguished professor of neurology and psychiatry at the University of California San Francisco. He is one of the leading researchers in the field of psychedelics and how they change neural circuitry in the brain. His laboratory is responsible for understanding, for instance, how psilocybin, also sometimes referred to as magic mushrooms, change neural circuitry in the brain such that new ideas and new forms of learning occur. His laboratory is also responsible for carrying out various clinical trials, some of which have demonstrated that appropriate dosages of psilocybin can alleviate major depression in more than 67% of people that take the drug. Now, this is not to say that everybody should take psilocybin, and today's discussion describes both the clinical trials and why treatments with psychedelics in some cases work and in some cases do not work in order to treat major depression, as well as discussions around psilocybin, lysergic acid diethylamide, sometimes also referred to as LSD, as well as DMT, and how these change the brain, and how those brain changes can relate to changes in mental health as it relates to depression and other psychiatric challenges, as well as how psychedelics are being applied in order to change neural circuitry for sake of expanding different aspects of the human mind, including creativity, intelligence, and much more. During today's discussion, Dr. Carhart-Harris teaches us about the history of the study of psychedelics, as well as how the legislature, that is the laws surrounding psychedelics, are evolving in the United States and elsewhere for the use of psychedelics to treat psychiatric challenges. By the end of today's discussion, you will have a thorough understanding of how psychedelics work, both in the short term during the actual journey or trip. In fact, much of my discussion today with Dr. Carhart-Harris talks about the different aspects of the psychedelic journey and how those relate to therapeutic outcomes. And of course, by the end of today's discussion, you will also understand the long-term effects of psychedelics, that is how they can actually rewire the brain. Before we begin, I'd like to emphasize that this podcast is separate from my teaching and research roles at Stanford. It is, however, part of my desire and effort to bring zero-cost to consumer information about science and science-related tools to the general public. In keeping with that theme, I'd like to thank the sponsors of today's podcast. Our first sponsor is Eight Sleep. Eight Sleep makes smart mattress covers with cooling, heating, and sleep tracking capacity. I've talked many times before on this podcast about the fact that sleep is the foundation of mental health, physical health, and performance. One absolutely critical variable to getting excellent sleep is the temperature of your sleeping environment. That is, in order to fall and stay deeply asleep at night, your body temperature needs to actually drop by about one to three degrees, and in order to wake up in the morning feeling refreshed and alert, your body temperature has to increase by about one to three degrees. There are a lot of ways to control the temperature of your sleeping environment, but one of the best ways is to control the temperature of your actual mattress, the surface that you're sleeping on. With Eight Sleep, you can do this very easily. There's a simple-to-use app where you can program in the temperature of your mattress across the night. So you can make it slightly cool at the beginning of the night, getting cooler, putting you into deep sleep and then rapid eye movement sleep, and all of that, in terms of its impact on your sleep, can be tracked within the same app. I've been sleeping on an Eight Sleep mattress cover for more than two years now, and it has completely transformed my sleep. If you'd like to try Eight Sleep, you can go to EightSleep.com/huberman for their exclusive Memorial Day savings now through June 5th, 2023. Eight Sleep currently ships in the USA, Canada, United Kingdom, select countries in the EU and Australia. Again, that's EightSleep.com/huberman. Today's episode is also brought to us by Levels. Levels is a program that lets you see how different foods affect your health by giving you real-time feedback on your diet using a continuous glucose monitor. One of the most important factors in terms of your energy levels and your immediate and long-term health are your blood glucose or blood sugar levels, as they're commonly called. With Levels, you can assess how different foods and activities impact your blood glucose levels. When I did this, it taught me several things. First of all, it taught me that certain foods really spike my blood glucose levels, and while spikes in blood glucose aren't always a bad thing, I was able to assess how certain foods were spiking my blood glucose too much, such that I would have post-eating dips in energy levels, and by removing those foods and substituting in other foods, really evened out my energy levels. So if you're interested in learning more about Levels and trying a continuous glucose monitor yourself, go to Levels.Link/huberman. Right now, Levels is offering an additional two free months of membership. Again, that's Levels.Link/huberman. Today's episode is also brought to us by HVMN Ketone IQ. Ketone IQ is a ketone supplement that increases blood ketones. Now, most people have heard of the so-called ketogenic diet, but most people, including myself, are not on the ketogenic diet. That is, I, and most people, eat complex carbohydrates, fruits and things of that sort, in addition to quality proteins, et cetera. It turns out that even if you're not following a ketogenic diet, increasing your blood ketones can still have benefits. So for instance, I use Ketone IQ anytime I want to do extended bouts of focused work, preparing for podcasts, research, writing grants, and if I ever want to exercise, but I don't have time to eat or I don't want to have my gut full of food. Taking Ketone IQ and thereby increasing my blood ketones allows me to do cognitive work or physical workouts without getting hungry and with plenty of energy and cognitive focus. If you'd like to try Ketone IQ, you can go to HVMN.com/huberman to save 20% off. Again, that's HVMN.com/huberman. I'm pleased to announce that I will be hosting two live events in September of 2023. The first live event will take place in Toronto on September 12th. The second live event will take place in Chicago on September 28th. Both live events will include a lecture and a question and answer period, and are entitled The Brain Body Contract, during which I will discuss tools and science related to mental health, physical health, and performance. And I should mention that a lot of that content will have absolutely no overlap with content covered previously on the Huberman Lab Podcast or elsewhere.If you're interested in attending either or both of these events, please go to hubermanlab.com/tour and enter the code Huberman to get early access to tickets. Once again, that's hubermanlab.com/tour and use the code Huberman to access tickets. I hope to see you there. And now for my discussion with Dr. Robin Carhart-Harris. Dr. Carhart-Harris, welcome. I've been wanting to talk to you for a long time. I certainly have known who you are for quite a while because I place you in this very small but very special and important category of researchers who has been pioneering the use of psychedelics for the treatment of specific clinical conditions and really, uh, carrying the torch for essentially the entire field. So I wanna start with a, a voice of gratitude and say thank you for doing this incredibly important work. Could you tell us a little bit about what psychedelics are? In fact, I'm curious as to how the name psychedelic ever came to be-
Install uListen to search the full transcript and get AI-powered insights
Get Full TranscriptGet more from every podcast
AI summaries, searchable transcripts, and fact-checking. Free forever.
Add to Chrome